Latest Quarterly Reports News

Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.

L1 Group Limited has completed its transformative merger between Platinum Asset Management and L1 Capital, creating a $16.7 billion funds under management powerhouse, backed by a $286 million capital raise to fuel growth.

Alkane Resources reported a strong Q1 FY2026 with $147 million in revenue and 30,511 gold equivalent ounces produced, bolstered by its recent merger with Mandalay Resources. The company’s balance sheet is solid with $191 million in cash and investments after repaying debt and covering merger costs.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Elixir Energy has received a $3.861 million R&D tax refund, providing crucial funding for its upcoming Taroom Trough appraisal drilling and production testing programs.

Image Resources NL has responded to an ASX price query following unusual trading activity, confirming no undisclosed material information exists. The company referenced a recent ABC article and negative assay results from a non-core gold project as unrelated factors.

ResMed Inc. reported a robust 9% increase in net revenue for Q1 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. Despite ongoing patent litigation, the company delivered a 12% rise in net income and boosted shareholder returns with a $150 million share repurchase.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

Challenger Gold Limited reported a solid cash position of A$27.7 million for Q3 2025, backed by strong financing activities and a funding runway exceeding five quarters. The company’s strategic financing arrangements underpin its ongoing exploration ambitions.

Infinity Mining’s latest quarterly report reveals promising high-grade gold assays at its Sir Walter Scott prospect in NSW and new exploration targets in Victoria, signaling renewed momentum in its Eastern Australian portfolio.

Tartana Minerals reports a significant new gold resource estimate at Cardross alongside robust copper sulphate sales and strategic board changes, positioning itself as a rising copper-gold producer in Far North Queensland.

Admiralty Resources NL reported a mixed cash flow quarter ending September 2025, balancing operating outflows with investing and financing inflows to maintain a solid funding runway.